All Oncology News

The OncLive® News page includes the latest in clinical oncology news, including breaking regulatory decisions, clinical trial findings, pivotal and practice-changing data published in academic peer-reviewed journals, and more across solid and hematologic malignancies. Regulatory news includes new drug approvals by the FDA and European Union, priority review and breakthrough therapy designations, and orphan drug and fast track statuses.

Blood Test Distinguishes Neuroendocrine Subtype of Advanced Prostate Cancer

January 16th 2024

Blood test uses cell-free DNA methylation to quantify tumor burden and distinguish neuroendocrine prostate cancer from prostate adenocarcinoma.

Discovering Fusions Requires More Than DNA Testing in GI Cancers

January 16th 2024

E. Gabriela Chiorean, MD, highlights the importance of consistently testing for biomarkers with RNA-based tests in addition to DNA-based tests.

EMA Grants Orphan Drug Designation to Pimicotinib for Inoperable TGCT

January 15th 2024

The European Medicines Agency has granted orphan drug designation to pimicotinib for use in patients with inoperable tenosynovial giant cell tumor.

Rate of End-of-Life Immunotherapy Is on the Rise in Advanced Melanoma, NSCLC, RCC

January 15th 2024

The initiation of immunotherapy at the end of life among patients with advanced cancers is increasing over time.

Investigational Targeted Therapies Broaden Glioma Research Efforts and Define Disease Subsets

January 15th 2024

Ashley Sumrall, MD, FACP, discusses ongoing research with the DRD2 dopamine receptor–targeted agent ONC201 in patients with H3K27M-mutated glioma.

ctDNA Patterns May Predict Outcomes Achieved With mRNA-4157 Plus Pembrolizumab in High-Risk Melanoma

January 15th 2024

Jeffrey S. Weber, MD, PhD, expands on the potential utility of longitudinal ctDNA dynamics as a kinetic marker for clinical outcomes in melanoma.

JBI-802 Demonstrates Preliminary Activity in Advanced Solid Tumors

January 15th 2024

Treatment with JBI-802, the first-in-class CoREST inhibitor with dual LSD1 and HDAC6 activity was shown to be safe and active.

EU Approval Sought for Frontline Lazertinib Plus Amivantamab in EGFR+ NSCLC

January 15th 2024

An MAA seeking the approval of lazertinib plus amivantamab in the first-line treatment of adult patients with EGFR+ NSCLC has been submitted to the EMA.

Florida Cancer Specialists & Research Institute Physicians Recognized for Expertise in 2023

January 15th 2024

Florida Cancer Specialists & Research Institute physicians were recognized in 2023 by several magazines as top doctors in their local communities.

ESMO 2023 Updates in Endometrial and Cervical Cancer Give Glimpse Into Future Care

January 15th 2024

Updated data from several clinical trials in endometrial and cervical cancer could signal the emergence of multiple effective options coming down the pike.

Male Breast Cancer Diagnosis Fuels Groundbreaking Treatment Tool

January 14th 2024

Doctors diagnosed Christopher Gregg, PhD, with stage IV metastatic breast cancer in 2018. Then, he started thinking of ways to improve his treatment.

Dana-Farber Cancer Institute and the Florez Laboratory Set to Launch Innovative Pregnancy and Lung Cancer Registry

January 14th 2024

The Florez Lab at Dana-Farber Cancer Institute is launching the innovative International Pregnancy and Lung Cancer Registry.

Florida Cancer Specialists & Research Institute Welcomes Radiation Oncologist Bradford Perez, MD in Pasco County

January 13th 2024

Florida Cancer Specialists & Research Institute, LLC is pleased to welcome radiation oncologist Bradford Perez, MD to the statewide practice.

Sequential Neoadjuvant HER2 Blockade Plus Polychemotherapy Elicits Antitumor Activity in HER2+ Breast Cancer

January 13th 2024

Neoadjuvant pegylated liposomal doxorubicin and cyclophosphamide, followed by a taxane, concomitant with trastuzumab/pertuzumab elicited responses in patients with HER2+ breast cancer.

FDA Approves Pembrolizumab Plus Chemoradiation for FIGO 2014 Stage III to IVA Cervical Cancer

January 12th 2024

The FDA has approved pembrolizumab (Keytruda) plus chemoradiation for patients with FIGO 2014 stage III to IVA cervical cancer.

Camrelizumab With Rivoceranib Elicits PFS and OS Benefit Over Sorafenib in Unresectable HCC

January 12th 2024

Amit Mahipal, MD, discusses clinical outcomes with camrelizumab plus rivoceranib in unresectable HCC, based on data from the phase 3 CARES-310 trial.

Neoadjuvant Cemiplimab Prolongs Survival in Stage II to IV CSCC

January 12th 2024

Neil D. Gross, MD, FACS, shares how neoadjuvant cemiplimab followed by surgery improved EFS in patients with stage II-IV cutaneous squamous cell carcinoma.

Addition of Multifocal MRI-Directed SIB to SBRT Shows Acceptable Toxicity Profile in Prostate Cancer

January 12th 2024

Joshua Hurwitz, MD, shares how multifocal MRI-directed SIB plus SBRT was not linked with added toxicity vs unifocal SIB in patients with prostate cancer.

Immunotherapy for Metastatic Cancer on the Rise, Even Near End of Life

January 12th 2024

Although use of immunotherapy near the end of life has increased over time, a closer look at the benefit of this in those with advanced cancers is needed.

FDA Grants Fast Track Designation to RC88 in Platinum-Resistant Recurrent Ovarian Cancer

January 12th 2024

The FDA has granted fast-track status to RC88 for use in patients with platinum-resistant recurrent epithelial ovarian cancer.